Get the Stockscreener App
748.72
1.06%
-8.04
After Hours:
755.00
6.28
+0.84%
Argen X Se Adr stock is traded at $748.72, with a volume of 453.22K.
It is down -1.06% in the last 24 hours and down -12.09% over the past month.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
See More
Previous Close:
$756.76
Open:
$748.13
24h Volume:
453.22K
Relative Volume:
1.29
Market Cap:
$46.33B
Revenue:
$3.06B
Net Income/Loss:
$1.28B
P/E Ratio:
38.06
EPS:
19.6719
Net Cash Flow:
$447.35M
1W Performance:
-10.90%
1M Performance:
-12.09%
6M Performance:
+3.70%
1Y Performance:
+20.26%
1-Day Range:
$743.78
$757.23
1-Week Range:
$743.78
$848.83
52-Week Range:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-24-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-15-25 | Resumed | Truist | Buy |
| Sep-11-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-08-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-13-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-17-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-12-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Strong Buy |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
RBC Capital Adjusts argenx SE ADR PT to $890 From $925, Maintains Outperform Rating - marketscreener.com
Your Kidneys Count: American Kidney Fund Urges Americans to Protect Their Health this Kidney Month - GlobeNewswire Inc.
ARGENX : Goldman Sachs gives a Buy rating - marketscreener.com
ARGENX : Deutsche Bank reiterates its Neutral rating - marketscreener.com
Stifel cuts argenx stock price target to $1,227 on valuation By Investing.com - Investing.com South Africa
Earnings call transcript: Argenx Q4 2025 sees strong earnings beat, stock dips - Investing.com
BofA raises argenx stock price target to $1,013 on trial success - Investing.com
Stifel cuts argenx stock price target to $1,227 on valuation - Investing.com
ARGENX : Gets a Buy rating from Goldman Sachs - marketscreener.com
Argenx's Vyvgart Improves Ocular Myasthenia Gravis Symptoms in Late-stage Trial - marketscreener.com
ARGENX : Receives a Buy rating from Bernstein - marketscreener.com
argenx ADR earnings beat by $2.07, revenue topped estimates - Investing.com
Argenx SE FY25 swings to profit as Vyvgart sales double - Investing.com
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Argenx Reports Higher FY25 Attributable Profit, Operating Income - marketscreener.com
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update - Sahm
Insights into argenx's Upcoming Earnings - Sahm
Artisan Mid Cap Fund Maintains Its Confidence in Argenx’s (ARGX) VYVGART - Insider Monkey
argenx to Present at TD Cowen 46th Annual Healthcare Conference - ChartMill
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues - Finviz
Increased Demand for Vyvgart Boosted Argenx SE (ARGX) in Q4 - Insider Monkey
Analysts May Have Underestimated Argenx SE's (ARGX) 5 year Revenue Growth - Finviz
Wells Fargo analyst sees potential in Argenx SE’s (ARGX) Vyvgart, increases PT to $1,317 - MSN
Goldman Sachs Assumes Penguin Solutions (PENG) Coverage with Buy Rating, $25 PT - Yahoo Finance
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Insider Monkey
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Yahoo Finance
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development - Yahoo Finance
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)’s 2026 Growth Despite Revenue Headwinds - Yahoo Finance
Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW) - Yahoo Finance
Assessing argenx (ENXTBR:ARGX) Valuation After Recent Share Price Pullback - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Vyvgart Priority Review Puts Argenx Valuation Gap And Pipeline In Focus - Yahoo Finance
Argenx's (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments - Finviz
Argenx’s (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments - Yahoo Finance
Wells Fargo Analyst Sees Potential in Argenx SE's (ARGX) Vyvgart, Increases PT to $1,317 - Finviz
argenx SE (ARGX): A Bull Case Theory - Finviz
Why Argenx SE (ARGX) Stock Advanced on Commercial Execution - Finviz
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Jefferies Keeps Their Buy Rating on Argenx Se (ARGX) - The Globe and Mail
Argenx shares rise as FDA reviews Vyvgart for broader use By Investing.com - Investing.com South Africa
Argenx shares rise as FDA reviews Vyvgart for broader use - Investing.com
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG - Sahm
William Blair reiterates Outperform rating on argenx stock - Investing.com
Argenx shares slip as Q4 results come in broadly in line By Investing.com - Investing.com South Africa
Argenx shares slip as Q4 results come in broadly in line - Investing.com
Wells Fargo Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Sahm
argenx SE stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
Argenx SE Announces CEO Changes - marketscreener.com
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):